Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63

• US 8,962,585 B2
• Filed: 12/29/2010
• Issued: 02/24/2015
• Est. Priority Date: 12/29/2009
• Status: Active Grant

• Current Assignee: CURNA, Inc. (Opko Health, Inc.)
• Original Assignee: CURNA, Inc. (Opko Health, Inc.)
• Inventors: Collard, Joseph, Khorkova Sherman, Olga
• Primary Examiner(s): WHITEMAN, BRIAN A
• Application Number:
  US13/519,477
• Publication Number:
  US 20120295953A1
• Time in Patent Office: 1,518 Days
• Field of Search: 514/44.A
• US Class Current: 514/44.A
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/12 for climacteric disorders
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/08 Antiseborrheics
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 17/16 Emollients or protectives, e.g. against radiation
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/113 targeting other non-coding nucleic acids, e.g. antagomirs
• CPC Class Codes: C12N 2310/31 : of the backbone
• CPC Class Codes: C12N 2310/315 : Phosphorothioates
• CPC Class Codes: C12N 2310/32 : of the sugar
• CPC Class Codes: C12N 2310/321 : 2'-O-R Modification
• CPC Class Codes: C12N 2310/3231 : having an additional ring, e.g. LNA, ENA
• CPC Class Codes: C12N 2310/33 : of the base
• CPC Class Codes: C12Q 1/6811 : Selection methods for production or design of target specific oligonucleotides or binding molecules

Abstract

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Protein 63 (p63), in particular, by targeting natural antisense polynucleotides of Tumor Protein 63 (p63). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of p63.

Claims

1. A method of upregulating a function of and/or the expression of a Tumor Protein 63 (p63) polynucleotide having SEQ ID NO:

1 or an isoform of p63 in mammalian cells or tissues in vivo or in vitro comprising;

contacting said cells or tissues with at least one antisense oligonucleotide of 12 to 30 nucleotides in length that specifically targets a region of a natural antisense polynucleotide of the Tumor Protein 63 (p63) gene having SEQ ID NO;

2;

thereby upregulating a function of and/or the expression of the Tumor Protein 63 (p63) polynucleotide in mammalian cells or tissues in vivo or in vitro.

2. The method of claim 1, wherein a function of and/or the expression of the Tumor Protein 63 (p63) is increased in vivo or in vitro with respect to a control.

3. The method of claim 1, wherein the at least one antisense oligonucleotide targets a natural antisense polynucleotide that is antisense to coding and/or non-coding nucleic acid sequences of a Tumor Protein 63 (p63) RNA polynucleotide transcribed by the p63 gene.

4. The method of claim 1, wherein the at least one antisense oligonucleotide targets a natural antisense polynucleotide having overlapping and/or non-overlapping sequences with a Tumor Protein 63 (p63) RNA polynucleotide transcribed from the p3 gene.

5. The method of claim 1, wherein the at least one antisense oligonucleotide comprises one or more modifications selected from:

at least one modified sugar moiety, at least one modified internucleoside linkage, at least one modified nucleotide, and combinations thereof.

6. The method of claim 5, wherein the one or more modifications comprise at least one modified sugar moiety selected from:

a 2′

-O-methoxyethyl modified sugar moiety, a 2′

-methoxy modified sugar moiety, a 2′

-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and combinations thereof.

7. The method of claim 5, wherein the one or more modifications comprise at least one modified internucleoside linkage selected from:

a phosphorothioate, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

8. The method of claim 5, wherein the one or more modifications comprise at least one modified nucleotide selected from:

a peptide nucleic acid (PNA), a locked nucleic acid (LNA), an arabino-nucleic acid (FANA), an analogue, a derivative, and combinations thereof.

9. The method of claim 1, wherein the at least one oligonucleotide comprises oligonucleotide SEQ ID NO:

5.

10. A method of upregulating a function of and/or the expression of a Tumor Protein 63 (p63) gene in mammalian cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for a overlapping region of a natural antisense polynucleotide of a Tumor Protein 63 (p63) polynucleotide having SEQ ID NO;

2; and

, upregulating a function of and/or the expression of Tumor Protein 63 (p63) in mammalian cells or tissues in vivo or in vitro.

11. A method of upregulating a function of and/or the expression of Tumor Protein 63 (p63) having SEQ ID NO:

1 or an isoform thereof in mammalian cells or tissues in vivo or in vitro comprising;

contacting said cells or tissues with at least one antisense oligonucleotide of about 10 to 30 nucleotides in length specific for a natural antisense polynucleotide of a Tumor Protein 63 (p63) polynucleotide having SEQ ID NO;

2 wherein said at least one antisense oligonucleotide has at least 80% sequence identity to at least one nucleic acid sequence set forth as SEQ ID NOS;

1 or an RNA polynucleotide encoded by the p63 gene; and

, upregulating the function and/or expression of the Tumor Protein 63 (p63) in mammalian cells or tissues in vivo or in vitro.

12. A method of upregulating the expression of Tumor Protein 63 (p63) transcript variant 3 polynucleotide or an isoform thereof and/or at least one encoded product thereof in a mammal, comprising:

administering to said mammal a dose of at least one antisense oligonucleotide of about 10 to 30 nucleotides in length that specifically binds to a natural antisense polynucleotide of said at least one Tumor Protein 63 (p63) polynucleotide having SEQ ID NO;

2 and upregulates expression of said at least one Tumor Protein 63 (p63) polynucleotide;

thereby upregulating the at least one Tumor Protein 63 (p63) polynucleotide and/or at least one encoded product thereof wherein the mammal has a skin condition or disorder or cancer.